Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects With FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia

Next Previous
Trial Profile

A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects With FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Quizartinib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Ambit Biosciences Corporation; Astellas Pharma; Daiichi Sankyo Inc

Most Recent Events

  • 29 Jun 2020 Results evaluating the population pharmacokinetics (PK) of quizartinib and its active metabolite published in the Journal of Clinical Pharmacology
  • 06 Nov 2019 Results of analysis of two clinical studies: a phase 3 QuANTUM-R trial and a phase 2 study APS2689-CL-2004, evaluating exposure response relationships across various efficacy endpoints of quizartinib, release in 61st Annual Meeting and Exposition of the American Society of Hematology
  • 06 Nov 2019 Results of pooled data from four studies: one phase 3 (QuANTUM-R), two phase 2, (ACC220-002 and 2689-CL-2004), and one phase 1 (CP0001), released at the 61st Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top